227 related articles for article (PubMed ID: 27157475)
1. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma.
Zhou H; He F; Mendelsohn CL; Tang MS; Huang C; Wu XR
Sci Rep; 2016 May; 6():25596. PubMed ID: 27157475
[TBL] [Abstract][Full Text] [Related]
2. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis.
He F; Mo L; Zheng XY; Hu C; Lepor H; Lee EY; Sun TT; Wu XR
Cancer Res; 2009 Dec; 69(24):9413-21. PubMed ID: 19951992
[TBL] [Abstract][Full Text] [Related]
4. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation.
Zhang ZT; Pak J; Huang HY; Shapiro E; Sun TT; Pellicer A; Wu XR
Oncogene; 2001 Apr; 20(16):1973-80. PubMed ID: 11360181
[TBL] [Abstract][Full Text] [Related]
5. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations.
Williamson SR; Wang M; Montironi R; Eble JN; Lopez-Beltran A; Zhang S; Fan R; Wang L; Osunkoya AO; Koch MO; Cheng L
Mod Pathol; 2014 Nov; 27(11):1540-8. PubMed ID: 24743222
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of urinary bladder cancer.
Al Hussain TO; Akhtar M
Adv Anat Pathol; 2013 Jan; 20(1):53-60. PubMed ID: 23232572
[TBL] [Abstract][Full Text] [Related]
7. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
Bernard-Pierrot I; Brams A; Dunois-Lardé C; Caillault A; Diez de Medina SG; Cappellen D; Graff G; Thiery JP; Chopin D; Ricol D; Radvanyi F
Carcinogenesis; 2006 Apr; 27(4):740-7. PubMed ID: 16338952
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.
Foth M; Ahmad I; van Rhijn BW; van der Kwast T; Bergman AM; King L; Ridgway R; Leung HY; Fraser S; Sansom OJ; Iwata T
J Pathol; 2014 Jun; 233(2):148-58. PubMed ID: 24519156
[TBL] [Abstract][Full Text] [Related]
10. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior.
Garcia-España A; Salazar E; Sun TT; Wu XR; Pellicer A
Cancer Res; 2005 Feb; 65(4):1150-7. PubMed ID: 15734997
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
[TBL] [Abstract][Full Text] [Related]
12. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
Shi MJ; Fontugne J; Moreno-Vega A; Meng XY; Groeneveld C; Dufour F; Kamoun A; Viborg Lindskrog S; Cabel L; Krucker C; Rapinat A; Dunois-Larde C; Lepage ML; Chapeaublanc E; Levrel O; Dixon V; Lebret T; Almeida A; De Reynies A; Rochel N; Dyrskjøt L; Allory Y; Radvanyi F; Bernard-Pierrot I
Eur Urol; 2023 Jan; 83(1):70-81. PubMed ID: 36273937
[TBL] [Abstract][Full Text] [Related]
13. Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.
Le Frère-Belda MA; Gil Diez de Medina S; Daher A; Martin N; Albaud B; Heudes D; Abbou CC; Thiery JP; Zafrani ES; Radvanyi F; Chopin D
Hum Pathol; 2004 Jul; 35(7):817-24. PubMed ID: 15257544
[TBL] [Abstract][Full Text] [Related]
14. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth.
Cheng J; Huang H; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Cancer Res; 2002 Jul; 62(14):4157-63. PubMed ID: 12124355
[TBL] [Abstract][Full Text] [Related]
16. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.
di Martino E; L'Hôte CG; Kennedy W; Tomlinson DC; Knowles MA
Oncogene; 2009 Dec; 28(48):4306-16. PubMed ID: 19749790
[TBL] [Abstract][Full Text] [Related]
17. Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
Dunois-Lardé C; Levrel O; Brams A; Thiery JP; Radvanyi F
Mol Carcinog; 2005 Mar; 42(3):142-9. PubMed ID: 15690367
[TBL] [Abstract][Full Text] [Related]
18. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.
Zhou H; Huang HY; Shapiro E; Lepor H; Huang WC; Mohammadi M; Mohr I; Tang MS; Huang C; Wu XR
Carcinogenesis; 2012 Apr; 33(4):770-80. PubMed ID: 22287562
[TBL] [Abstract][Full Text] [Related]
19. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis.
Gao J; Huang HY; Pak J; Cheng J; Zhang ZT; Shapiro E; Pellicer A; Sun TT; Wu XR
Oncogene; 2004 Jan; 23(3):687-96. PubMed ID: 14737103
[TBL] [Abstract][Full Text] [Related]
20. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
